Xencor’s (XNCR) Sell Rating Reiterated at Zacks Investment Research

Zacks Investment Research reiterated their sell rating on shares of Xencor (NASDAQ:XNCR) in a research report released on Saturday morning.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

Several other analysts have also recently issued reports on XNCR. ValuEngine cut shares of Xencor from a hold rating to a sell rating in a research note on Monday, October 23rd. BidaskClub cut shares of Xencor from a sell rating to a strong sell rating in a research note on Friday, December 15th. Piper Jaffray Companies reaffirmed a buy rating and set a $35.00 price target on shares of Xencor in a research report on Sunday, November 12th. Cantor Fitzgerald initiated coverage on shares of Xencor in a research report on Wednesday, November 29th. They set an overweight rating and a $33.00 price target for the company. Finally, Canaccord Genuity set a $36.00 price target on shares of Xencor and gave the stock a buy rating in a research report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Xencor has a consensus rating of Hold and a consensus target price of $30.80.

Shares of Xencor (XNCR) opened at $22.50 on Friday. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64. The stock has a market cap of $1,060.00, a price-to-earnings ratio of -22.28 and a beta of 2.09.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%. analysts anticipate that Xencor will post -1.1 EPS for the current year.

In other news, major shareholder John S. Stafford III acquired 24,653 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was bought at an average cost of $20.01 per share, with a total value of $493,306.53. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder John S. Stafford III acquired 50,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was purchased at an average cost of $19.58 per share, with a total value of $979,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 278,535 shares of company stock valued at $5,526,936. 4.14% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of XNCR. Great West Life Assurance Co. Can boosted its position in Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 4,005 shares during the last quarter. SG Americas Securities LLC boosted its position in Xencor by 62.6% in the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares during the last quarter. Legal & General Group Plc boosted its position in Xencor by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the last quarter. Principal Financial Group Inc. purchased a new position in Xencor in the 3rd quarter valued at about $201,000. Finally, Citadel Advisors LLC purchased a new position in Xencor in the 2nd quarter valued at about $224,000. 77.50% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.truebluetribune.com/2018/01/16/xencors-xncr-sell-rating-reiterated-at-zacks-investment-research.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply